ArticleScientific reports2026
Cost of illness of Mycoplasma genitalium in Australia: an incidence-based approach incorporating resistance-guided therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
As macrolide-resistant Mycoplasma genitalium (MG) becomes more prevalent, resistance-guided therapy (RGT) for MG has been recommended in clinical guidelines to improve first-line antibiotic selection and increase cure rates. This study adopted an incidence-based approach and a healthcare sector perspective to measure the cost of illness of MG in Australia. Two management strategies, RGT and non-RGT, were examined. A decision tree model was developed to replicate the clinical pathways among non-pregnant women, men who have sex with men (MSM) and men who have sex with women (MSW). The burden of managing a woman diagnosed with MG was lower under RGT compared to non-RGT (AUD 249 vs. 283). For MSM, the expected per-person cost was AUD 240 and AUD 279 under RGT and non-RGT. For MSW, non-RGT would cost an additional AUD 23. Overall, this study found that the economic burden of MG under RGT is lower than under non-RGT for both women and men in Australia. RGT offers cost savings while improving MG clinical management and helping to slow the spread of macrolide resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.